Who are Losartan/amlodipine or losartan/hydrochlorothiazide's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/losartan-amlodipine-or-losartan-hydrochlorothiazide.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Losartan/amlodipine or losartan/hydrochlorothiazide — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Losartan/amlodipine or losartan/hydrochlorothiazide (Losartan/amlodipine or losartan/hydrochlorothiazide) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Angiotensin II receptor blocker combination (ARB + calcium channel blocker or ARB + thiazide diuretic). Area:

marketed Angiotensin II receptor blocker combination (ARB + calcium channel blocker or ARB + thiazide diuretic) Angiotensin II type 1 receptor (AT1R); L-type voltage-gated calcium channels (amlodipine) or sodium-chloride cotransporter (hydrochlorothiazide) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Losartan/amlodipine or losartan/hydrochlorothiazide (Losartan/amlodipine or losartan/hydrochlorothiazide) — Yokohama City University Medical Center. This is a fixed-dose combination of losartan (an angiotensin II receptor blocker) with either amlodipine (a calcium channel blocker) or hydrochlorothiazide (a thiazide diuretic) to lower blood pressure through multiple complementary pathways.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Losartan/amlodipine or losartan/hydrochlorothiazide TARGET	Losartan/amlodipine or losartan/hydrochlorothiazide	Yokohama City University Medical Center	marketed	Angiotensin II receptor blocker combination (ARB + calcium channel blocker or ARB + thiazide diuretic)	Angiotensin II type 1 receptor (AT1R); L-type voltage-gated calcium channels (amlodipine) or sodium-chloride cotransporter (hydrochlorothiazide)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Angiotensin II receptor blocker combination (ARB + calcium channel blocker or ARB + thiazide diuretic) class)

Yokohama City University Medical Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Losartan/amlodipine or losartan/hydrochlorothiazide — Competitive Intelligence Brief. https://druglandscape.com/ci/losartan-amlodipine-or-losartan-hydrochlorothiazide. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab